Teva appears to have altered plans to launch in the near future its generic version of Amarin’s Vascepa (icosapent ethyl), despite entering into a settlement agreement with the originator more than three years ago opening the door for market entry.
The Israeli firm’s icosapent ethyl abbreviated new drug application products – both 500mg and 1g capsules – are now listed...




